Category Archives: Endocrinology

Family’s participation key to advancing diabetes research | VUMC … – VUMC Reporter

When half of their six children were diagnosed with what was then believed to be Type 1 diabetes, David and Ellen Pursell decided their family would participate in research related to the health condition. This family photo from several years ago includes, seated, from left, Peggy, Ramsey and Chrissy. Standing, from left, are Vaughan, Ellen, Martin, David and Parker.

by Jill Clendening

Individuals with Type 1 diabetes have a smaller pancreas than people without diabetes. This is surprising because the pancreatic islets and their insulin-producing beta cells account for just a small fraction of the pancreas, so the loss of beta cells in Type 1 diabetes would not be expected to reduce pancreas size.

Now, a study of one family from Alabama has led Vanderbilt University Medical Center researchers to discover that insulin deficiency, independent of the autoimmunity associated with Type 1 diabetes, is the principal factor leading to a markedly smaller pancreas.

Four members of this family of eight have monogenic diabetes from a rare mutation in the insulin gene, leading to insulin deficiency without autoimmunity. Magnetic resonance imaging (MRI) of the pancreas showed a reduced size and altered shape in the individuals with diabetes. This reduction in size was similar to what had previously been observed in individuals with Type 1 diabetes. These new findings are published in Diabetes Care, a journal of the American Diabetes Association.

While persons with Type 1 diabetes typically have multiple genes that are known to contribute to the development of the autoimmune disorder, individuals with a single mutation that only impacts the insulin gene provided the investigators a unique opportunity to examine the impact of that single factor on pancreas size.

This is a wonderful story about the power of a single family to inform us about the process of a disease that affects millions of people, said Daniel Moore, MD, PhD, associate professor of Pediatrics in the Ian Burr Division of Pediatric Endocrinology and Diabetes. There are not many families, especially not large families, who are known to have exactly this form of diabetes, who could come forward to help us answer this question. But they responded to the call, and theyve provided a really clear answer to a very fundamental biologic question.

About two decades ago, David Pursell and his wife, Ellen, agreed that he and three of their six children who were diagnosed with diabetes would participate in research with the hope more could be learned about the disease. It was as simple as giving a little blood.

They were surprised years later when a researcher from the University of Chicagos Kovler Diabetes Center called to tell them that advances in science had revealed that the four actually had monogenic diabetes due to a mutation in the insulin gene instead of Type 1 diabetes.

Their care remained the same daily monitoring of their blood glucose and multiple doses of insulin each day.

Several more years went by before science came knocking again. Last year, the Pursells were contacted by a team of VUMC researchers who were collaborating with Siri Greeley, MD, PhD, and colleagues at the Kovler Diabetes Centers Monogenic Diabetes Registry at the University of Chicago. The Vanderbilt research team asked if the family could travel to Nashville to have precise measurements of their pancreas taken at the Medical Center.

The VUMC research team, which includes Moore, Jordan Wright, MD, PhD, Jon Williams, PhD, Melissa Hilmes, MD, and Alvin C. Powers, MD, along with colleague Jack Virostko, PhD, at The University of Texas at Austin, had previously found the reduction in pancreas size was present at the time of Type 1 diabetes diagnosis. The Vanderbilt investigators had also organized an international team, the Multicenter Assessment of the Pancreas in Type 1 Diabetes, to develop a standardized MRI imaging protocol to assess pancreas volume and microarchitecture.

We know the pancreas is much smaller in individuals with Type 1 diabetes, but there havent been good models to understand exactly whats going on, said Jordan Wright, MD, PhD, an instructor in the Division of Diabetes, Endocrinology and Metabolism and first author on the manuscript.

One hypothesis is that the autoimmune process of Type 1 diabetes also affects the exocrine part of the pancreas. This is the first time we can actually demonstrate in humans that insulin is a major factor in determining pancreas size and the loss of it leads to a much smaller pancreas.

David and Ellen and their now adult children, Peggy Rice, Vaughan Spanjer, Chrissy Adolf, Ramsey Nuss, and twin sons Parker and Martin Pursell, each had their pancreas size measured using the standardized Vanderbilt MRI protocol. David, Chrissy, Parker and Martin have monogenic diabetes; the rest of the family does not.

When we talked to some of the doctors at Kovler in Chicago, they asked if wed be interested in participating in some trials or research and we said, Of course, anything we can do, said David Pursell. Part of it, Ill admit, was selfish. When we learned our diabetes was not caused by an immune response due to our islet cells being attacked by antibodies, then we thought maybe weve got the chance of getting an islet cell transplant.

But also, were obviously all in this together. If, by virtue of our family volunteering for this research we can help anyone else, we felt like it would be worth it.

The Vanderbilt investigators, as part of MAP-T1D, are building on this study by measuring pancreas size in individuals at known risk of developing diabetes and correlating those measurements with the imminence of a diabetes diagnosis. They also are examining whether reduced pancreas size correlates with other issues such as the need for pancreatic enzymes to support digestion.

This research was performed with assistance from the Vanderbilt University Institute of Imaging Sciences (National Institutes of Health [NIH] project 1S10OD021771-01), the Vanderbilt Institute for Clinical and Translational Research (UL1-TR000445) and the Institute for Translational Medicine (UL1-TR000430) and with the support of the Leona M. and Harry B. Helmsley Charitable Trust, the Juvenile Diabetes Research Foundation, the Doris Duke Charitable Foundation, the NIH (DK104942, DK129979) and the Vanderbilt and Chicago Diabetes Research and Training Centers (DK20593, DK20595).

View post:

Family's participation key to advancing diabetes research | VUMC ... - VUMC Reporter

Lee Health has several big projects in the works in Cape Coral – Naples Daily News

Surfside Medical expansion getting under way in next month or two; service growth at Cape Coral Hospital in the works

Lee Health has numerous projects in the works to address health care needs in fast-growing Cape Coral.

They range from adding physician offices so more specialty services are closer to home for residents, including pediatric care, to expansions at Cape Coral Hospital, according to Dave Kistel, vice president and chief facilities executive.

The board for the publicly-operated hospital system recently approved a contract amendment to expand the Surfside Medical Facility at Veterans Parkway and Surfside Boulevard. The total project cost is $10.4 million and is targeted for completion in January 2024.

The phase-two project involves adding 15,000 square feet of space to the two-story outpatient complex.

Specialists employed by Lee Physician Group in orthopedics, endocrinology, rheumatology, and rehabilitation medicine will go into the new space.

Lee Physician Group currently does not have specialists in orthopedics or endocrinology in Cape Coral so that will become a first in both fields, Kistel said. Rheumatologists have been part time and will become available full time, he said. Outpatient-based rehabilitation medicine has been available at Cape Coral Hospital but is maxed out so the expansion at Surfside will offer a second location.

Overall the expansion of Surfside will mean some patients wont need to commute to Fort Myers for specialty care with Lee Physician Group and wait times to see other specialists will improve, Kistel said.

Cape Coral and its geographic area of 120 square miles has faced steady population growth and is now the eighth largest city in Florida with 204,510 residents, upfrom 154,305 residents in 2010. City leaders in 2021 projected 50-year growth to 430,000 residents.

Forbes Magazine last year ranked Cape Coral as the fourth best place to live in Florida, ahead of Orlando at fifth place and Miami as the sixth best place to live. The first three are Tampa, Jacksonville, and Gainesville.

Forbes pegged median income of Cape residents at around $62,000 and the median home price at $479,000.

Therese Everly, Lee Health board member whose district includes Cape Coral, said the hospital system is committed to expanding services and access to health care throughout the region as Southwest Florida continues to grow.

This is a very exciting time in Cape Coral as we have several new projects underway," she said. "Cape Coral Hospital is the foundation of healthcare in the community, and were proud to be investing in innovative projects in the Cape, such as Bimini Basin, which is community-based."

There's been positive impact bringing internal medicine residency program through Florida State University College of Medicine to Cape Coral, she said.

"Through this residency program and clinic, Lee Health is developing well-educated, highly trained physicians, creating greater accessibility to needed care in the community," Everly said.

The 291-bed Cape hospital is getting some add-ons to keep up with both inpatient and outpatient demand.

Lee Health is planning to lease 47,000 square feet of building space in the future $100 million Bimini Basin project that is in the works by a developer in south Cape Coral.

The Cape Coral City Council approved rezoning and the master concept in February for the mixed-use development with apartments, a waterfront restaurant and shops on three sites south of Cape Coral Parkway.

The plan in the leased space is to offer laboratory services, radiology, womens breast and health care and adult cardiology. The space also will be used for pediatric services in primary care, rehabilitation medicine and behavioral health.

Its a pretty substantial complement of physicians at that site, Kistel said.

When Lee Health will gain access to the leased space depends on the developers time line for construction, he said.

Originally posted here:

Lee Health has several big projects in the works in Cape Coral - Naples Daily News

Hypothalamic inflammation and obesity, study suggests a pathological mechanism – News-Medical.Net

In a recent review published in the European Journal of Endocrinology, researchers discussed current research on the relationship between human obesity and inflammation of the hypothalamus.

Study: Is human obesity an inflammatory disease of the hypothalamus? Image Credit:SciePro/ Shutterstock

In 2022, the World Health Organization (WHO) declared that obesity was a pandemic in Europe, with 60% of the adult population being obese or overweight. Obesity directly reduces longevity and also increases the risk of various other diseases such as cardiovascular diseases, type 2 diabetes, hyperlipidemia, hypertension, gout, and various types of cancers.

Metabolic inflammation and its association with obesity is an area of research that has recently gained attention. Metabolic inflammation involves low-grade chronic inflammation in peripheral tissues such as adipose tissue, the liver, and the hypothalamus. The hypothalamus is thought to be the brain center that regulates appetite and body weight. While hypothalamic inflammation has been studied in animal models and humans, recent research is examining whether hypothalamic inflammation might not be a consequence of obesity but a cause.

The arcuate nucleus in the mediobasal hypothalamus integrates various peripheral endocrine factors and regulates appetite and the feeling of satiety. Two groups of functionally antagonistic neurons are located in the arcuate nucleus. The neuropeptide Y and orexigenic agouti-related peptide neurons form one group, and the anorexigenic proopiomelanocortin and the cocaine and amphetamine-regulated transcript form the other, and all four of these first-order neurons are involved in regulating satiety and appetite. These neurons also express insulin and leptin receptors, which are directly linked to nutrition and energy storage in the body.

Other gastrointestinal tract hormones such as glucagon-like peptide-1, ghrelin, and cholecystokinin can also stimulate the neurons in the arcuate nucleus, mediating appetite and feelings of satiety.

Metabolic inflammation is the moderate but persistent overexpression of pro-inflammatory signals, which has been observed in adipose tissue, the pancreas, the liver, and the hypothalamus. Studies indicate that hypothalamic inflammation is initiated due to different types of metabolic triggers but not body weight. Furthermore, cells such as perivascular macrophages, astrocytes, microglia, and neurons are also involved in the initiation of chronic hypothalamic inflammation. The crosstalk between glia and astrocytes is thought to play a role in the health of the central nervous system (CNS) and various CNS-related diseases.

Some chemokines involved in the feedback between glia and astrocytes have been linked to obesity-associated inflammation. In response to triggers, microglia are thought to secrete pro-inflammatory signals that activate astrocytes. Since astrocytes express leptin and insulin receptors, the sustained activation and feedback between astrocytes and glial cells impact energy homeostasis.

Studies on mice models have found that a hyperlipidemic diet has been linked to impaired insulin signaling and expression of inflammatory response proteins and cytokines in the hypothalamus. Other studies have also associated chronic high-fat diets with increased pro-inflammatory signaling. Saturated fatty acids such as stearic, arachidic, and behenic acids are thought to significantly increase the secretion of pro-inflammatory mediators.

Diets that have a high carbohydrate content have also been linked to the activation of microglia and hypothalamic inflammation. While astrogliosis is linked mainly to lipid metabolism and diets high in sucrose, have resulted in hypothalamic inflammation in mice without astrogliosis, a fructose-rich diet was shown to induce astrogliosis and increase the production of cytokines. Western diets are thought to contain large amounts of saturated fatty acids and monosaccharides commonly, and studies have found links between metabolic inflammation and Western diets and lifestyle. Additionally, factors such as imbalances in the gut microbiome, age-related changes, and neuronal overactivity could be other triggers of hypothalamic inflammation.

High-fat diets are thought to trigger hypothalamic inflammation through various signaling pathways, including toll-like receptor 4, c-Jun N-terminal kinases, protein kinase C, and ceramide pathways, and the induction of endoplasmic reticulum stress.

A method involving T2-relaxation time-weighted magnetic resonance imaging (MRI) had been used to detect hypothalamic inflammation and gliosis in obese individuals. Post-mortem biopsies have also linked gliosis in the hypothalamus to higher body mass index values.

Overall, the findings suggested that hypothalamic inflammation could be a cause and not merely a consequence of obesity. This is supported by the observation that hypothalamic inflammation occurred even before weight gain after the ingestion of high-fat diets. In addition, research on animal models and recent translational human studies have established a link between hypothalamic inflammation and obesity. The development of MRI techniques to detect hypothalamic inflammation could potentially identify targets for pharmaceutical interventions to treat or manage obesity.

Written by

Chinta Sidharthan is a writer based in Bangalore, India. Her academic background is in evolutionary biology and genetics, and she has extensive experience in scientific research, teaching, science writing, and herpetology. Chinta holds a Ph.D. in evolutionary biology from the Indian Institute of Science and is passionate about science education, writing, animals, wildlife, and conservation. For her doctoral research, she explored the origins and diversification of blindsnakes in India, as a part of which she did extensive fieldwork in the jungles of southern India. She has received the Canadian Governor Generals bronze medal and Bangalore University gold medal for academic excellence and published her research in high-impact journals.

Please use one of the following formats to cite this article in your essay, paper or report:

APA

Sidharthan, Chinta. (2023, March 14). Hypothalamic inflammation and obesity, study suggests a pathological mechanism. News-Medical. Retrieved on March 15, 2023 from https://www.news-medical.net/news/20230314/Hypothalamic-inflammation-and-obesity-study-suggests-a-pathological-mechanism.aspx.

MLA

Sidharthan, Chinta. "Hypothalamic inflammation and obesity, study suggests a pathological mechanism". News-Medical. 15 March 2023. <https://www.news-medical.net/news/20230314/Hypothalamic-inflammation-and-obesity-study-suggests-a-pathological-mechanism.aspx>.

Chicago

Sidharthan, Chinta. "Hypothalamic inflammation and obesity, study suggests a pathological mechanism". News-Medical. https://www.news-medical.net/news/20230314/Hypothalamic-inflammation-and-obesity-study-suggests-a-pathological-mechanism.aspx. (accessed March 15, 2023).

Harvard

Sidharthan, Chinta. 2023. Hypothalamic inflammation and obesity, study suggests a pathological mechanism. News-Medical, viewed 15 March 2023, https://www.news-medical.net/news/20230314/Hypothalamic-inflammation-and-obesity-study-suggests-a-pathological-mechanism.aspx.

Go here to see the original:

Hypothalamic inflammation and obesity, study suggests a pathological mechanism - News-Medical.Net

American Society for Clinical Investigation honors physician … – Washington University School of Medicine in St. Louis

Visit the News Hub

3 early-career scientists recognized for achievements in research at WashU

Three physician-scientists whose research occurred at Washington University School of Medicine in St. Louis have been honored with the Young Physician-Scientist Award by the American Society for Clinical Investigation. From left, they are Abby Margaret Green, MD; Parker C. Wilson, MD, PhD; and Jing Hughes, MD, PhD.

Three early-career scientists who have conducted their research at Washington University School of Medicine in St. Louis have been honored with the Young Physician-Scientist Award by the American Society for Clinical Investigation (ASCI). They are Abby Margaret Green, MD; Jing Hughes, MD, PhD; and Parker C. Wilson, MD, PhD.

The honor recognizes 50 physician-scientists nationwide who are early in their careers and have had notable achievements in their research. The award supports their involvement with three scientific associations offering leadership development workshops, panel discussions with ASCI members, virtual poster sessions and other career-enhancing activities.

Green, an assistant professor of pediatrics and of pathology & immunology, focuses on the causes of genetic mutations associated with pediatric and adult-onset cancers. She studies how specific enzymes, which cause damage to DNA, promote the development and progression of cancer. The goal of her research is to develop targeted therapies for cancer. In the process, Greens lab emphasizes mentorship. She is affiliated with Siteman Cancer Center and Siteman Kids, and the Roy and Diana Vagelos Division of Biology & Biomedical Sciences.

Hughes, an assistant professor of medicine in the Division of Endocrinology, Metabolism & Lipid Research, studies pancreatic cells that produce hormones that drive glucose metabolism, a key factor in processing and storing energy in the body. Type 1 and Type 2 diabetes can result when glucose levels are too high. Specifically, she analyzes the role in diabetes of an organelle called the primary cilium. Hughes is funded by the National Institutes of Health (NIH) and has established collaborations with other scientists to study the structure and function of pancreatic cells.

Wilson formerly an assistant professor in the Division of Anatomic and Molecular Pathology within the Department of Pathology & Immunology, and the universitys Institute of Clinical and Translational Sciences researches single cell biology and the genetics of kidney disease. Previously, Wilson was a fellow in WashUs Molecular Genetic Pathology program. Earlier this year, he accepted a tenure-track position at the University of Pennsylvania; however, the award recognizes his research conducted at Washington University.

For more information on the awards, please visit ASCI.

Read the original:

American Society for Clinical Investigation honors physician ... - Washington University School of Medicine in St. Louis

Pediatric Investigation review takes stock of history and current … – EurekAlert

image:The growth hormone somatotropin is directly involved in regulating growth in children, and continues to play a role in adulthood. Long-acting growth hormone is now available in most global markets and will positively impact growth hormone therapies by reducing the treatment burden on the patient. view more

Credit: Pediatric Investigation

In 1957, Maurice Raben successfully isolated and purified the growth hormone (GH) from the pituitary gland, opening up a potential avenue of GH therapies. Children who were born with a deficiency of this hormone could now receive medical intervention in the form of daily injections to substitute the product into their body, thus avoiding the ill-effects of GH deficiency. However, given that it was a product that had to be meticulously extracted from the pituitary of dead bodies, and was time-consuming as well as labor- and resource-intensive process, it remained available only in limited quantities, wherein only a few patients could be treated.

A few years later, in 1985, recombinant-DNA generated GH became available that could be produced in laboratories and in much larger quantities. As a result, it became more easily available and accessible for treating children with GH deficiency. However, one drawback these therapies suffered from was the need to take daily injections of the hormone to ensure that it was available in appropriate concentrations in the blood.

A recent review article published in Pediatric Investigation on 03 January 2023 has now taken stock of the clinical development in GH therapy since its isolation, outlining how far we have come and where we are headed with the use of GH therapy. The physiological regulation of GH involves a complex mechanism that depends on several age-related and metabolic factors. This regulatory mechanism releases GH doses into the bloodstream every three hours. While this mechanism remained a theoretical interest from clinical perspectives, researchers tried to synthesize a recombinant GH that could integrate itself seamlessly into the mechanism, explains corresponding author Dr. Paul Saenger, who is a professor at NYU Long Island School of Medicine. The goal was to produce a pharmaceutical product that would remain active in the body and mimic this pulsatile release of the hormone such that a daily dose would not be necessary.

A prototype of such a long-acting growth hormone (LAGH) was developed by LG Life Sciences in 2014 and the research data were made publicly available. Over the next few years, multiple research labs and pharmaceutical companies have fine-tuned this original prototype, developing many LAGH products.

The review begins with a discussion on the clinical evolution of GH therapy from a historical perspective, followed by a deep dive into the hormonal rationale for GH therapies, development phases and mechanisms involved in these different LAGH products. It then goes on to highlight the considerations patients and their families must keep in mind when planning a LAGH therapy, and its overall role in improving GH therapies.

The mechanisms underlying novel LAGH action involve either a formulation that forms a subcutaneous deposit to allow the release of native/modified GH hormone in a pulsatile manner similar to the actual GH release patterns in the body, or injecting it as a substance that can be easily absorbed in the bloodstream but is removed slowly such that the same pulsatile release can be maintained.

With these developments, LAGH therapies now only require a weekly or monthly dose instead of a daily intake, greatly reducing the burden of injection on the patient. This, in turn, is likely to improve patient compliance. LAGH-based products like Jintrolong and Lonapegsomatropin have already cleared phase 3 trials and are being marketed in China and USA respectively, while Somatrogon has been approved in Europe and Canada.

The clinical use of GH is an exciting success story. We are now entering a new era of LAGH therapy with new formulations of GH, which will predictably be the preferred form of therapy for years to come. Additionally, the availability of new safety data will further establish its use in clinical medicine, comments Dr. Saenger.

While further research on dosage regulation and timing is still underway for other forms of LAGH, their availability in international markets certainly paints a bright picture.

***

Reference

Authors: Margaret Steiner, Jacklyn Frank, and Paul Saenger

DOI: https://doi.org/10.1002/ped4.12358

Affiliations:

NYU Langone Health-Long Island, 101 Mineola Boulevard, Mineola, New York, USA

About Dr. Paul Saenger

Dr. Paul Saenger is a Professor of Pediatrics Emeritus,Albert Einstein College of Medicine, Professor of Pediatrics at NYU Langone HospitalLong Island, Visiting Professor of Munich University, Visiting Professor of Beijing Children's Hospital. He received his training at the New York Hospital/Cornell Medical Center in Pediatric Endocrinology. He treats patients with growth disorders, diabetes mellitus, and disorders of puberty and the thyroid. Taking care of both children and their families, he helps them formulate realistic expectations and cope with their diagnoses. With more than 40 years of experience in the field, he has trained more than 45 fellows who currently work in pediatric endocrinology.

Pediatric Investigation

Literature review

Not applicable

Long-acting growth hormone in 2022

3-Jan-2023

The authors declare that they have no conflict of interest

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Link:

Pediatric Investigation review takes stock of history and current ... - EurekAlert

Progyny Enhances Male Fertility Offering with the Expansion of its … – GlobeNewswire

NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) a leading benefits management company specializing in fertility and family building benefits solutions, today announced the expansion of its provider network to include reproductive urologists (RU). Patients with Progynys comprehensive and equitable solution will now have convenient access to high-quality urological care, in addition to the existing Progyny network made up of more than 650 clinics and over 950 leading fertility specialists.

Currently, about one third of infertility cases are due to one partner being unable to create and ejaculate healthy sperm, often referred to as male-factor infertility. While Progyny has already been covering several treatments for sperm-related infertility through its reproductive endocrinology and infertility (REI) network, there are those who need further evaluation from a RU, a doctor who specializes in reproductive health for people who produce sperm. Progyny is proud to now offer coverage and access to a curated network of accredited RUs for those individuals.

Infertility impacts millions of people and sperm related infertility accounts for a sizable portion, yet most of the conversation and responsibility falls to the female population, said Pete Anevski, Progynys CEO. At Progyny, we work to address all areas of infertility to provide the best services and treatments possible to ensure everyones dreams of parenthood are realized. Expanding our male fertility offering to include a RU network of best-in-class physicians is a vital step to furthering this mission.

To expand Progynys provider network, the company worked closely with its well-respected REI partners to distinguish RUs that provide best-in-class urological care. Each RU has been vetted to meet Progynys network standards and will work collaboratively with the REIs to ensure a streamlined and cohesive patient experience.

I am very excited to be involved in the roll-out of Progynys extended coverage for male-factor infertility. This is a great opportunity for patients to have expanded coverage to optimize their chances of achieving their family building goals, said Dr. Shane Russell, a reproductive urologist in Progynys network. The Progyny team has been great to work with and I look forward to a long and productive partnership with them.

To find a reproductive urologist in Progynys network, please visit: https://providersearch.progyny.com/.

About Progyny

Progyny (Nasdaq: PGNY) is a leading fertility benefits management company. We are redefining fertility and family building benefits, proving that a comprehensive and inclusive solution can simultaneously benefit employers, patients, and physicians.

Our benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists using the latest science and technologies, reduces healthcare costs for the nations leading employers, and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so.

Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcares Best Places to Work in Healthcare, Financial Times, INC. 5000, and Crains Fast 50 for NYC. For more information, visit http://www.progyny.com.

See the original post:

Progyny Enhances Male Fertility Offering with the Expansion of its ... - GlobeNewswire